Patents by Inventor Clyde L. Schultz

Clyde L. Schultz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160158320
    Abstract: Hydrogel lenses are infused with a drug for the treatment of posterior segment disease. The lenses are placed in contact with the subject's cornea. Drugs can be passively released from the hydrogel and can migrate around the globe of the eye to the posterior segment.
    Type: Application
    Filed: December 7, 2015
    Publication date: June 9, 2016
    Applicant: DIRECT CONTACT LLC
    Inventors: Clyde L. Schultz, Jerome J. Schentag
  • Patent number: 9216106
    Abstract: Hydrogel lenses are infused with a drug for the treatment of posterior segment disease. The lenses are placed in contact with the subject's cornea. Drugs can be passively released from the hydrogel and can migrate around the globe of the eye to the posterior segment.
    Type: Grant
    Filed: September 2, 2008
    Date of Patent: December 22, 2015
    Assignee: DIRECTCONTACT LLC
    Inventors: Clyde L. Schultz, Jerome J. Schentag
  • Patent number: 7618643
    Abstract: The present invention features hydrogel drug delivery systems and methods of producing and using such systems for the treatment of wounds. The systems are based on a hydrogel into which a low concentration of growth factor, e.g., epidermal growth factor, is passively transferred from a dilute aqueous solution. When placed in contact with a wounded tissue, the growth factor passively transfers out of the contact lens to provide accelerated healing. The systems are applicable to ocular and other wound treatments.
    Type: Grant
    Filed: April 1, 2005
    Date of Patent: November 17, 2009
    Assignee: DirectContact LLC
    Inventor: Clyde L. Schultz
  • Publication number: 20080318843
    Abstract: Hydrogel lenses are infused with a drug for the treatment of posterior segment disease. The lenses are placed in contact with the subject's cornea. Drugs can be passively released from the hydrogel and can migrate around the globe of the eye to the posterior segment.
    Type: Application
    Filed: September 2, 2008
    Publication date: December 25, 2008
    Applicant: DirectContact LLC
    Inventors: Clyde L. Schultz, Jerome J. Schentag
  • Patent number: 7169406
    Abstract: The present invention features hydrogel drug delivery systems and methods of producing and using such systems for the treatment of wounds. The systems are based on a hydrogel into which a low concentration of growth factor, e.g., epidermal growth factor, is passively transferred from a dilute aqueous solution. When placed in contact with a wounded tissue, the growth factor passively transfers out of the contact lens to provide accelerated healing. The systems are applicable to ocular and other wound treatments.
    Type: Grant
    Filed: January 10, 2003
    Date of Patent: January 30, 2007
    Assignee: DirectContact LLC
    Inventor: Clyde L. Schultz
  • Publication number: 20030203032
    Abstract: The present invention features hydrogel drug delivery systems and methods of producing and using such systems for the treatment of wounds. The systems are based on a hydrogel into which a low concentration of growth factor, e.g., epidermal growth factor, is passively transferred from a dilute aqueous solution. When placed in contact with a wounded tissue, the growth factor passively transfers out of the contact lens to provide accelerated healing. The amount of growth factor absorbed into the hydrogel is low, e.g., ≦350 ppb, but this amount has surprisingly been found to be effective in producing a therapeutic effect. The systems are applicable to ocular and other wound treatments.
    Type: Application
    Filed: April 25, 2002
    Publication date: October 30, 2003
    Inventor: Clyde L. Schultz
  • Publication number: 20030203001
    Abstract: The present invention features hydrogel drug delivery systems and methods of producing and using such systems for the treatment of wounds. The systems are based on a hydrogel into which a low concentration of growth factor, e.g., epidermal growth factor, is passively transferred from a dilute aqueous solution. When placed in contact with a wounded tissue, the growth factor passively transfers out of the contact lens to provide accelerated healing. The systems are applicable to ocular and other wound treatments.
    Type: Application
    Filed: January 10, 2003
    Publication date: October 30, 2003
    Inventor: Clyde L. Schultz
  • Publication number: 20020197300
    Abstract: The invention features polymeric hydrogel contact lenses containing an anti-glaucoma medication, such as a beta adrenergic receptor antagonist, e.g., timolol maleate, or an alpha adrenergic receptor agonist, e.g., brimonidine tartrate, and methods of fabrication and uses thereof. A medication is passively transferred into a contact lens by absorption from a dilute aqueous solution. Such treated lenses are contacted with the ocular fluid of an individual to treat glaucoma.
    Type: Application
    Filed: June 25, 2002
    Publication date: December 26, 2002
    Inventors: Clyde L. Schultz, Janet M. Mint
  • Patent number: 5723131
    Abstract: A contact lens made of a polymeric hydrogel material having absorbed therein as a leachable additive of desferrioxamine, and a method for making the composition by soaking the polymeric material in a solution of the additive.
    Type: Grant
    Filed: December 28, 1995
    Date of Patent: March 3, 1998
    Assignee: Johnson & Johnson Vision Products, Inc.
    Inventors: Clyde L. Schultz, Ivan M. Nunez, David L. Silor, Michele L. Neil
  • Patent number: 5472703
    Abstract: An ophthalmic lens for placement on the anterior surface of the eye is disclosed. The lens has impregnated in it or it has coated on its surface an ester of a polyhydric aliphatic alcohol and a fatty acid in which the alcohol residue has at least one hydroxyl group. The ester is present in an amount which is effective to prevent or decrease the release of bacterial toxins when the lens is exposed to those toxins. The lens is particularly well-suited for a soft hydrogel contact lens, and advantageously eliminates, minimizes or prevents keratitis. Bacterial keratitis is an infection of the cornea of the eye which may occur during extended wear of the lens and may cause ulceration of the cornea.
    Type: Grant
    Filed: March 2, 1993
    Date of Patent: December 5, 1995
    Assignee: Johnson & Johnson Vision Products, Inc.
    Inventors: Douglas G. Vanderlaan, Susan K. Brown-Skrobot, Clyde L. Schultz